Abstract
Introduction
A characteristic feature of human cancers is a deregulation of the normal balance between proliferation and cell death, which is crucial to maintain tissue homeostasis [1] . Accordingly, too little cell death can contribute to tumour formation [2] . Apoptosis (programmed cell death) is a form of cell death that is highly conserved throughout evolution and plays an important role on the control of various physiological and pathological processes [3] . Evasion of apoptosis is one of the hallmarks of human cancers including pancreatic carcinoma. In addition, defects in apoptosis programs can contribute to the primary or acquired resistance of pancreatic carcinoma to therapies that are currently used in the clinic, because the response of cancer cells to current treatment approaches is, to a large extent, due to their ability to undergo cell death in response to cytotoxic stimuli [4] [5] [6] . Thus, a better understanding of the regulation of apoptosis signalling in pancreatic cancer cells is expected to identify novel molecular targets in pancreatic cancer that can be exploited for the development of molecular targeted therapies.
Pancreatic cancer
Pancreatic cancer is one of the leading causes of cancer deaths in the western world with steadily rising numbers [7, 8] . The prognosis of patients with the diagnosis of pancreatic cancer is very poor despite intensive protocols [7] . Resistance of pancreatic cancer to current treatment regimens contributes to the dismal prognosis of this malignancy and presents a major challenge in oncology [9] . Evasion of apoptosis, the cell's intrinsic cell death program, is a characteristic feature of human cancers including pancreatic carcinoma and promotes the development and progression of pancreatic cancer [10] . Also [11] . Caspases are cysteine proteases that are synthesized as inactive proenzymes and become activated upon cleavage [11] .
The death receptor (extrinsic) pathway and the mitochondrial (intrinsic) pathway are the two principal pathways of apoptosis that fuel into activation of caspases (Fig. 1) [3] [14] . In addition, AIF has been described to mediate caspase-independent death and large scale DNA fragmentation after release from mitochondria [15] . Most cytotoxic drugs are considered to primarily initiate cell death by triggering a cytochrome c/Apaf-1/caspase-9 dependent pathway linked to mitochondria [16] .
Besides [12, 18] . This death domain is crucial for transmitting the death signal from the cell's surface to intracellular signalling pathways and serves as a docking platform for the recruitment of adaptor and signalling molecules [12, 18] [12, 19] . This in turn leads to caspase-8 activation, which can then directly cleave downstream effector caspases such as caspase-3 [12] . [57] . Above all, Smac peptidomimetics were developed on the basis of the 3D structure of Smac in complex with XIAP BIR3 [58] . These Smac peptidomimetics were reported to enhance radiosensitivity of pancreatic carcinoma cells by promoting ␥-irradiation-induced caspase activation and apoptosis [52] .
The CD95 receptor/CD95 ligand system is a key regulator of apoptosis in the immune system as well as in immunosurveillance of cancer [18]. CD95 is expressed on activated lymphocytes, on a variety of tissues of lymphoid origin and also on tumour cells [18]. CD95 ligand is produced by cytotoxic T cells and can trigger autocrine suicide or paracrine death in lymphocytes and also contributes to tumour immunosurveillance by killing cancer cells [18]. For example, pancreatic cancer cells have been reported to evade Fas-mediated immune surveillance by expressing a non-functional CD95 receptor or by aberrant expression of CD95 ligand on their surface to 'counterattack' cytotoxic T-cells [20].

Fig. 1 Apoptosis pathways. Apoptosis pathways can be initiated by ligation of death receptors such as TRAIL receptors (TRAIL-Rs) by their respective ligands, e.g. TRAIL, followed by receptor trimerization, recruitment of adaptor molecules (FADD) and activation of caspase-8 (receptor pathway). The mitochondrial pathway is initiated by the release of apoptogenic factors such as cytochrome c or Smac from mitochondria in the cytosol. Apoptosis can be inhibited by Bcl-2 or by 'inhibitor of apoptosis proteins' (IAPs). Smac promotes apoptosis by neutralizing IAP-mediated inhibition of caspase-
. Analysis of molecular events revealed that bortezomib triggered up-regulation of TRAIL-R1/TRAIL-R2, formation of the TRAIL DISC, down-regulation of the anti-apoptotic protein c-FLIPL and accumulation of the pro-apoptotic protein Bak, thereby tipping the balance towards apoptosis [37]. Moreover, the addition of certain phenoxazine derivatives enhanced the cytotoxicity of TRAIL [38]. While there are additional anticancer agents that have been reported to act in concert with TRAIL in pancreatic cancer, the examples given above support the concept that TRAIL-based regimens of pancreatic cancer will likely be combination protocols. In a search for biomarkers that predict sensitivity to TRAIL, a correlation between the expression of specific O-glycosylation enzymes and the response to TRAIL was recently identified in certain cancer types including pancreatic cancer [39]. O-glycosyltransferases are overexpressed in several cancers and may regulate TRAIL-induced apoptosis via modulation of TRAIL-R1 or -R2, as these two agonistic TRAIL receptors harbour O-glycosylation sites that facilitate TRAIL-mediated receptor aggregation, DISC formation and activation of caspase-8 [39]. In order to exploit the TRAIL system for clinical application, various agents have been developed in recent years [22]. These include recombinant soluble TRAIL as well as agonistic antibodies directed against the apoptosis inducing TRAIL receptors, i.e. TRAIL-R1 and -R2 [40, 41]. Apomab, an agonistic antibody against TRAIL-R2, was recently reported to show antitumour activity against pancreatic cancer as single agent and also in combination with gemcitabine [42]. As far as pancreatic carcinoma is concerned, fully human TRAIL-R1 monoclonal antibodies are currently under evaluation in a phase I clinical trial for advanced solid tumours in combination with gemcitabine and cisplatin [43] (Table 1). It is important to note, TRAIL has been reported to exert also non-apoptotic functions under certain conditions, which has been linked to its ability to stimulate survival cascades such as NF-B, PI3K/Akt or Ras/Raf/ERK pathways [44]. For example, TRAIL promoted metastasis of human pancreatic carcinoma in an orthotopic mouse model [45]. This indicates that the design of TRAIL-based combination regimens should take into consideration not only to enhance apoptosis induction by TRAIL, but in addition to prevent the tumour promoting activities of TRAIL.
Targeting 'inhibitor of apoptosis proteins' (IAPs) for pancreatic cancer therapy
IAPs are a family of endogenous caspase inhibitors that comprise eight human analogues, i.e. XIAP, cIAP1, cIAP2, surviving, livin (ML-IAP), NAIP, Bruce (apollon) and ILP-2 [46]. Classification as IAP protein requires the existence of at least one baculovirus IAP repeat (BIR) domain, which is also the domain that interacts with caspases. Among the IAP family proteins, XIAP is considered to exert the most potent anti-apoptotic effects
Furthermore, the natural product embelin from the Japanese Ardisia herb was discovered in a computational screening of a traditional herbal medicine 3D structure database as a cell-permeable, non-peptidic, small-molecular weight inhibitor of XIAP [59] . In cell-based assays, embelin was shown to increase TRAILinduced apoptosis in pancreatic carcinoma cells [60] .
There are also small molecule compounds that were designed against the BIR2 domain of XIAP. For example, screening of a polyphenylurea library yielded several non-peptidic molecules that displayed potent binding to BIR2 of XIAP [61, 62] . Because XIAP interacts with effector caspase-3 and -7 via its BIR2 domain, while the BIR3 domain is responsible for its binding to the initiator caspase-9, it has been argued that targeting the BIR2 domain might be superior over BIR3 [61, 62] . Accordingly, these polyphenylurea compounds triggered apoptosis in pancreatic carcinoma cells without the requirement of an additional cytotoxic stimulus [49] . Also, they potentiated the response of pancreatic carcinoma cells to several cytotoxic stimuli including gemcitabine, TRAIL or irradiation [49] . [67] . ABT-737 is the prototypic compound that has been extensively studied in preclinical models [68] . By preventing the binding of these anti-apoptotic Bcl-2 proteins to Bax or Bak, the small molecule inhibitor can directly trigger apoptosis in some susceptible cell lines or sensitize cancer cells for apoptosis [67] . Recently, ABT-737 has been shown to synergistically enhance TRAIL-mediated cytotoxicity in pancreatic cancer cell lines by promoting the cross-talk between the extrinsic and intrinsic apoptotic pathways [69] . Further, the BH3 mimetic obatoclax that also antagonize Mcl-1 in addition to Bcl-2, Bcl-XL and Bcl-w [70] has recently been reported to potentiate TRAIL-induced apoptosis in human pancreatic cancer cells [71] . An orally available second generation compound with improved pharmacokinetic properties, ABT-263, is currently under evaluation in early clinical trials in smallcell lung cancer and B-cell malignancies [72] . Also TW-37, another small-molecule inhibitor of Bcl-2, was shown to inhibit cell growth and invasion and increased apoptosis in pancreatic cancer [73] . Further, Bcl-XL antisense oligonucleotides increased the sensitivity of pancreatic cancer cells to gemcitabine or irradiation [74] [75] [76] . 
Conclusions
